Erin Colgan
2021
In 2021, Erin Colgan earned a total compensation of $1.2M as Chief Financial Officer at Sensei Biotherapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $123,600 |
|---|---|
| Option Awards | $764,586 |
| Salary | $317,812 |
| Other | $11,780 |
| Total | $1,217,778 |
Colgan received $764.6K in option awards, accounting for 63% of the total pay in 2021.
Colgan also received $123.6K in non-equity incentive plan, $317.8K in salary and $11.8K in other compensation.
Rankings
In 2021, Erin Colgan's compensation ranked 8,066th out of 12,415 executives tracked by ExecPay. In other words, Colgan earned more than 35.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,066 out of 12,415 | 35th |
Division Manufacturing | 3,569 out of 5,508 | 35th |
Major group Chemicals And Allied Products | 1,583 out of 2,378 | 33rd |
Industry group Drugs | 1,407 out of 2,099 | 33rd |
Industry Pharmaceutical Preparations | 1,044 out of 1,549 | 33rd |
Source: SEC filing on June 15, 2023.
Colgan's colleagues
We found two more compensation records of executives who worked with Erin Colgan at Sensei Biotherapeutics in 2021.